CCM
PLRX icon

CAAS Capital Management’s Pliant Therapeutics PLRX Stock Holding History

CAAS Capital Management’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-25,000
Closed -$566K – 905
2020
Q3 		$566K Hold
25,000
– – 0.01% 382
2020
Q2 		$812K Buy
+25,000
New +$664K 0.03% 285

Other funds holding PLRX

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

CAAS Capital Management's PLRX Position: Q4 2020 in Review

CAAS Capital Management sold out of Pliant Therapeutics (PLRX) in Q4 2020, closing a stake of 25,000 shares — an estimated $566K sold.

CAAS Capital Management first reported a position in PLRX in Q2 2020 and held it in 2 quarters. The position peaked at $812K in Q2 2020. 61 funds tracked by Wall St. Rank hold PLRX as of Q4 2020.

  • CAAS Capital Management reported no remaining Pliant Therapeutics position as of Q4 2020 after selling out during the quarter.
  • CAAS Capital Management sold 25,000 Pliant Therapeutics shares in Q4 2020, an estimated $566K.
  • CAAS Capital Management first reported a position in Pliant Therapeutics in Q2 2020 and held it in 2 quarters.
  • CAAS Capital Management's Pliant Therapeutics position peaked at $812K in Q2 2020.
  • 61 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q4 2020.

Based on CAAS Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.